SpainTuberculosis profile
Population  2018 47 million
Estimates of TB burdenº, 2018 Number (thousands) Rate
(per 100 000 population)
Total TB incidence 4.4 (3.8–5.1) 9.4 (8.1–11)
HIV-positive TB incidence 0.31 (0.11–0.63) 0.67 (0.23–1.4)
MDR/RR-TB incidenceºº 0.24 (0.17–0.33) 0.52 (0.36–0.71)
HIV-negative TB mortality 0.26 (0.26–0.27) 0.56 (0.55–0.57)
HIV-positive TB mortality 0.048 (0.014–0.1) 0.1 (0.03–0.22)
Estimated proportion of TB cases with MDR/RR-TB, 2018
New cases 4.2% (2.9–5.8)
Previously treated cases 18% (9.4–30)
TB case notifications, 2018  
Total new and relapse 4 500
          - % tested with rapid diagnostics at time of diagnosis 26%
          - % with known HIV status  
          - % pulmonary 72%
          - % bacteriologically confirmedººº 85%
          - % children aged 0-14 years 7%
          - % women 34%
          - % men 59%
Total cases notified 4 648
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2018 100% (89–120)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2018 7% (6–9)
TB/HIV care in new and relapse TB patients, 2018 Number (%)
Patients with known HIV status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2018
% of bacteriologically confirmed TB cases tested for rifampicin resistance ººº
          - New cases  
          - Previously treated cases  
Laboratory-confirmed cases* MDR/RR-TB: , XDR-TB:
Patients started on treatment* ** MDR/RR-TB: , XDR-TB:
MDR/RR-TB cases tested for resistance to second-line drugs  
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2017 61% 4 527
Previously treated cases, excluding relapse, registered in 2017 73% 1 125
HIV-positive TB cases registered in 2017 52% 217
MDR/RR-TB cases started on second-line treatment in 2016 44% 16
XDR-TB cases started on second-line treatment in 2016   0
TB preventive treatment, 2018  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2019  
National TB budget (US$ millions)  
º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Incidence graph
   Total TB incidence
   New and relapse TB cases notified
   HIV-positive TB incidence

(Rate per 100 000 population per year)
Mortality graph
   HIV-negative TB mortality

Notified cases by age group and sex, 2018
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2019-11-14 Data: www.who.int/tb/data